Healthcare entity

Thomas Burns

Person

medical-devices is the sole category represented across all 1 tracked stories. Glaukos Corporation is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 5 original sources each. Thomas Burns appears in 1 tracked Healthcare story from February 21, 2026.

Last mentioned: Feb 21, 2026

Entity pulse

Recent coverage · Thomas Burns

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Thomas Burns

medical-devices is the sole category represented across all 1 tracked stories. Glaukos Corporation is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 5 original sources each. Thomas Burns appears in 1 tracked Healthcare story from February 21, 2026.

Stories tracked
1
Sources per story
5

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Thomas Burns. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 2025 Earnings

    Both companies report record performance and optimistic 2026 outlooks.

  2. Payer Milestone

    Talkspace surpasses 140 million covered lives through payer partnerships.

  3. Talkspace Profitability

    Talkspace achieves its first full quarter of adjusted EBITDA profitability.

  4. Commercial Launch

    Initial rollout of iDose TR begins in the U.S. market with targeted accounts.

  5. iDose TR FDA Approval

    Glaukos receives landmark approval for its travoprost intracameral implant.

Stories mentioning Thomas Burns 1

Thomas Burns is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.